Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xalnesiran - Dicerna Pharmaceuticals

Next Previous
Search
Drug Profile

Xalnesiran - Dicerna Pharmaceuticals

Alternative Names: DCR HBV; DCR-HBVS; DCR-S219; GalXC therapy - Dicerna Therapeutics; RG-6346; RO-7445482

Latest Information Update: 08 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Developer Dicerna Pharmaceuticals; Roche
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 08 Nov 2024 Discontinued - Phase-II for Hepatitis B (Combination therapy, Treatment-experienced) in New Zealand, United Kingdom, Thailand, Taiwan, Spain, South Korea, Hong Kong, China, Canada, France, Bulgaria, Chile, Bulgaria, Belgium, Belgium, USA, Romania (SC)
  • 05 Jun 2024 Updated efficacy and adverse event data from the phase II PIRANGA trial in Hepatitis B was presented at the European Association for the Study of the Liver Congress (EASL-2024)
  • 09 May 2024 Roche plans to submit regulatory application for the approval of xalnesiran for Hepatitis B in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top